Summary: 1. S-1, a new oral anti-tumor drug, is composed of 5-fluoro-l-(tetrahydro-2-furanyl) 2,4(1H,3H)-pyrimidinedione (Tegafur, FT), 5-chloro-2,4-dihydroxypyridine (Gimestat, CDHP) and potassium 1,2,3,4-tetrahydro-2,4-dioxo-1,3,5-triazine-6-carboxylate(potassium otastat, Oxo) at a molar ratio of 1 : 0.4: 1. FT which is masked compound of 5-Fluorouracil (5-FU) plays a role as an effector com pound. Both CDHP and Oxo which do not have antitumor activity themselves play roles as modulators.After administration of S-1 or FT to tumor bearing rats, the Cmax and AUC of 5-FU were 20.8 pmol/ml and 207.6 pmol•hr/ml, in FT group and 1,192.0 pmol/ml and 5,203.0 pmol•hr/ml, in S-1 group. Thus, the S-1 group showed higher plasma 5-FU levels by 57 times in Cma., and by 25 times in AUC than those in the FT group. Similar to the plasma concentration, the concentration of 5-FU in tumor in the S-1 group was also higher than that in the FT group by 23 times in Cmax and by 16 times in AUC.2. After administration of S-1 to tumor bearing rats, the plasma concentration of CDHP, the reversible competitive inhibitor of dihydropyrimidine dehydrogenase (EC1.3.1.2), showed a Cm value of 2,054.8 pmol/ml at 30 min post-dose. The concentration of Oxo, the inhibitor of orotate phosphoribosyltransferase (EC2.4.2.10), in small intestine showed a Cmax value of 36,156.5 pmol/g at 30 min post-dose, and showed still high concentration of 2,813.6 pmol/g even at 3 hr post-dose.3. AUC of 5-FU in plasma and various tissues after administration of S-1 were found to be greater than those AUC after administration of UFT (combination of FT and uracil). AUC of fluoroureidopropionic acid (FUPA) and fluoro-/3-alanine (FBAL) in the S-1 group were smaller than those in the UFT group.